vTv Therapeutics

vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer. It offers Azeliragon, TTP399, TTP273, HPP593, HPP737, and the Nrf2/Bach1 program. The company was founded on April 2, 2015 and is headquartered in High Point, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shares of micro-cap biotech vTv Therapeutics Inc (NASDAQ: VTVT) were advancing to their highest level since October 2018 Monday following a clinical readout from the company.

VTV Therapeutics Shares Hit 16-Month High After Diabetes Drug Aces Midphase Study

GW Pharmaceuticals

Moderna

These drug stocks all have tremendous potential as these small companies work to treat widespread diseases in the U.S. and beyond.

3 Up-and-Coming Drug Stocks to Buy Now

vTv Therapeutics (VTVT) delivered earnings and revenue surprises of 9.09% and -99.53%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

VTv Therapeutics (VTVT) Reports Q3 Loss, Misses Revenue Estimates

AC Immune

Intra-Cellular Therapies

Here we discuss six small-cap companies with promising candidates in their pipeline for Alzheimer's disease.

6 Small Drug Stocks in Focus Ahead of World Alzheimer's Day

Patients treated with TTP399 had improved Time in Range (TIR), reduced time in hyperglycemia, fewer hypoglycemic events, and lower bolus insulin dose Patients treated with TTP399 had improved Time in Range (TIR), reduced time in hyperglycemia, fewer hypoglycemic events, and lower bolus insulin dose

vTv Therapeutics Presents Additional Positive Data from the Phase 2 Simplici-T1 Study in Patients with Type 1 Diabetes at 55th Annual Meeting of the European Association for the Study of Diabetes

The thinly traded micro-cap biotech vTv Therapeutics Inc (NASDAQ: VTVT) is on investors' radars ahead of a Sept.

Biotech Stock On The Radar: vTv Therapeutics' Diabetes Pipeline

 Presenting New Clinical Data from Phase 2 Study in Type 1 Diabetes with Liver Selective GKA Program

vTv Therapeutics to Present Posters at Two Scientific Conferences in September

HIGH POINT, N.C., Sept.  04, 2019  (GLOBE NEWSWIRE) --  vTv Therapeutics Inc.  (Nasdaq: VTVT), a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for diabetes and Alzheimer’s disease, today announced that it is scheduled to present a general company update at the H.C. Wainwright 21st Annual Global Investment Conference on Tuesday, September 10, 2019 at 3:00 p.m. Eastern Time in New York City. Company management will also be meeting with members of the investment community during one-on-one meetings at the conference.

vTv Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference

AMAG Pharmaceuticals

Ares Management

RealPage

Sunrun

WhiteHorse Finance

The GuruFocus All-in-One Screener can be used to find insider trades from the past week.

Largest Insider Trades of the Week (June 28)

vTv Therapeutics is currently trading at a super low stock price, indicating a potential buy for a high risk/return.

VTv Therapeutics: Unreasonably Cheap

News for vTv Therapeutics Stock (VTVT)